A
Alcista
Alcista · 25%RGC
$19.32
Precio del escenario
$9.590
+0.071 (+0.74%)Al cierre
Loading chart…
- Máximo
- 10.330
- Apertura
- 10.305
- Precio medio ponderado por volumen
- 9.58
- Volumen
- 688.21K
- Capitalización
- 45.81M
- Mínimo
- 8.830
- Importe
- 6.60M
- EV/EBITDA, TTM
- 0.00
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Análisis de IA of Regencell Bioscience Holdings Ltd (RGC)
ComprarRegencell Bioscience Holdings Ltd is a good buy right now due to its recent strong performance, with a 5-day change of +30.48% and a significant increase in trading volume at 688,207 shares, which is 2.44 times the 20-day average. However, the stock has a high RSI of 86.065, indicating it may be overbought in the short term, presenting a risk if the momentum reverses.
Recomendaciones de analistas (15)
Comprar
9 Comprar
5 Mantener
1 Vender
Actual: 9.59
Mínimo
—
Promedio
—
Máximo
—
Métricas de valoración
El PER previsto actual de Regencell Bioscience Holdings Ltd (RGC) es 0.00, frente a su media de 5 años de 0.00.
Escenarios de precio de Alphio AI para RGC
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
2.007-01seekingalphaRegencell Bioscience Shares Surge 35% Amid Short Squeeze
7.006-23PRnewswireRegencell Bioscience Faces Class Action Lawsuit
7.006-23GlobenewswireRegencell Bioscience Class Action Alert for Investors
- 7.006-23PRnewswire
Regencell Securities Class Action Reminder
- 7.006-22Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
Preguntas frecuentes sobre RGC, respondidas por Alphio AI
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).
Regencell Bioscience Holdings Ltd is a good buy right now due to its recent strong performance, with a 5-day change of +30.48% and a significant increase in trading volume at 688,207 shares, which is 2.44 times the 20-day average. However, the stock has a high RSI of 86.065, indicating it may be overbought in the short term, presenting a risk if the momentum reverses.
15 analysts cover RGC: 9 rate it Buy, 5 Hold and 1 Sell.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.